Mourad W A
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Pathology. 1997 Aug;29(3):255-9. doi: 10.1080/00313029700169015.
Sclerosing adenosis (SA) of the breast if a disease associated with an increase relative risk of malignancy. The exact incidence and factors influencing malignant transformation in association with SA are not well established. Two counts of the AgNOR silver staining technique have been correlated with ploidy and proliferative activity. The first count which is the mean number of AgNOR granules (mAgNOR), correlates with ploidy. The second count is the percentage of nuclei exhibiting > or = 5 AgNORs/nucleus (pAgNOR) and reflects proliferative activity. The hypothesis in the current study was that aneuploidy, as determined by the AgNOR silver staining technique, may potentially identify lesions of SA with an increased association with malignant breast disease. The AgNOR silver staining technique was performed on 69 cases of SA with the application of the two counts. Of these cases 53 were not associated with malignancy and 16 were associated with synchronous or metachronous carcinoma of the breast, these being 11 cases of invasive ductal carcinoma (IDC), four cases of ductal carcinoma in situ (DCIS) and one case of lobular carcinoma in situ (LCIS). The patient ages ranged from 27 to 84 years (median 53 years) with a median follow up of 28 months. Six of the 53 cases of SA no associated with malignancy (11%) had aneuploid mAgNOR counts of > or = 2.4 whereas 12 of the 16 cases associated with carcinoma (80%) had such counts (p < 0.0005). This included nine cases of IDC, two cases of DCIS and the case of LCIS. Of the six aneuploid cases not associated with malignancy, two cases showed cytological atypia, one case was associated with atypical ductal hyperplasia and one case was seen in a leukemic patient who had received chemotherapy and radiation therapy. The pAgNOR counts showed a statistically less significant correlation with malignancy (p < 0.03). These findings suggest that aneuploidy, measured by the AgNOR silver stein, seen in SA may help identify lesions with a higher relative risk of being associated with breast carcinoma and hence that may require more aggressive management than diploid ones.
乳腺硬化性腺病(SA)是一种与恶性肿瘤相对风险增加相关的疾病。与SA相关的恶性转化的确切发病率及影响因素尚未完全明确。AgNOR银染色技术的两项计数已与倍性和增殖活性相关联。第一项计数是AgNOR颗粒的平均数(mAgNOR),与倍性相关。第二项计数是显示≥5个AgNOR/核的细胞核百分比(pAgNOR),反映增殖活性。本研究的假设是,通过AgNOR银染色技术确定的非整倍体可能潜在地识别出与乳腺恶性疾病关联增加的SA病变。对69例SA病例进行了AgNOR银染色技术并应用了这两项计数。在这些病例中,53例与恶性肿瘤无关,16例与乳腺同步或异时癌相关,其中11例为浸润性导管癌(IDC),4例为导管原位癌(DCIS),1例为小叶原位癌(LCIS)。患者年龄范围为27至84岁(中位数53岁),中位随访时间为28个月。53例与恶性肿瘤无关的SA病例中有6例(11%)的mAgNOR计数为非整倍体且≥2.4,而16例与癌相关的病例中有12例(80%)有此类计数(p<0.0005)。这包括9例IDC、2例DCIS和1例LCIS。在6例与恶性肿瘤无关的非整倍体病例中,2例显示细胞学异型性,1例与非典型导管增生相关,1例见于接受化疗和放疗的白血病患者。pAgNOR计数与恶性肿瘤的相关性在统计学上不太显著(p<0.03)。这些发现表明,SA中通过AgNOR银染色所见的非整倍体可能有助于识别与乳腺癌关联相对风险较高的病变,因此可能比二倍体病变需要更积极的处理。